# Reneo Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reneo-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.reneopharma.com
- Total disclosed funding: $72M
- Latest round: Series B (Dec 9, 2020)
- Investors on record: 9

## About

Reneo Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicated to developing therapies aimed at mitochondrial diseases and rare metabolic disorders, enhancing cellular energy production and improving patient outcomes.Founded in 2014 and headquartered in San Diego, US, Reneo Pharmaceuticals, Inc. focuses on developing therapeutics for mitochondrial diseases. The company has successfully raised a total of USD 5.00 mn through various funding rounds, including a Private Placement/Follow on in May 2023. The current CEO is Gregory Flesher, who has guided the company through its growth and development.Reneo Pharmaceuticals specializes in the development of innovative therapeutics to address mitochondrial diseases and rare metabolic disorders. Their pipeline includes drug candidates targeting mitochondrial dysfunction, particularly aimed at enhancing cellular energy production and reducing oxidative stress. Reneo Pharma serves a range of stakeholders including healthcare providers, specialty pharmacies, and patients, primarily focusing on rare disease specialists and clinics treating complex metabolic disorders.Reneo Pharmaceuticals generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions. Revenue is primarily derived from milestone payments and royalties linked to their clinical programs, as well as potential future product sales upon successful commercialization. The pricing structures of their offerings are aligned with the value provided, catering to the specific needs of healthcare systems and patients.Reneo Pharmaceuticals plans to leverage its recent funding of USD 5.00 mn secured through a private placement in May 2023 to advance the development of REN001 across several areas of unmet need, including primary mitochondrial myopathies, fatty acid oxidation disorders, and McArdle disease. The company aims to expand its market presence further into the US and select European markets, enhancing its therapeutic offerings by targeting the needs of healthcare providers and patients suffering from rare metabolic conditions.

## Funding rounds

- Series B, Dec 9, 2020, $47M — Abingworth, New Enterprise Associates, Pappas Capital, RiverVest Ventures Partners, Novo Holdings, Aisling Capital, Lundbeckfond Ventures, Rock Springs Capital, Amzak Capital Management
- Series A, May 1, 2019, $25M — New Enterprise Associates, Pappas Capital, RiverVest Ventures Partners, Lundbeckfond Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A, Series B
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series A, Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A, Series B
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B
- Novo Holdings — Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B
- Rock Springs Capital — Series B
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series B